NCT00495755View on ClinicalTrials.gov

Campath in Chronic GVHD

PHASE1CompletedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

October 31, 2011

Study Completion Date

October 31, 2012

Conditions

Chronic Graft-vs.-Host Disease

Interventions

DRUG

Alemtuzumab (Campath)

An escalating dose given over 4 weeks

Trial Locations (1)

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Genzyme, a Sanofi Company

INDUSTRY

collaborator

Bayer

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER